On February 11, S&P Global released The Sustainability Yearbook 2025, which is hailed as the "authoritative guide" and "gold standard" in the field of global sustainable development. Sino Biopharm (1177.HK) was included for the first time due to its continuous efforts and high-level ESG governance in this field. Only 5 Chinese pharmaceutical companies were selected this time.

The publication of S&P Global's The Sustainability Yearbook 2025 (Global Edition) aims to identify and recognize outstanding companies worldwide that have demonstrated exceptional sustainability advantages in their respective industries. According to data disclosed by S&P, more than 7,690 companies from 62 industries worldwide participated in this year's S&P Corporate Sustainability Assessment (CSA). A total of 780 companies were included in The Sustainability Yearbook 2025 (Global Edition), with only 5 Chinese pharmaceutical companies selected.

Since its establishment, Sino Biopharm has firmly practiced the concept of sustainability, committed to achieving "science for a healthier world". In recent years, the Group has comprehensively promoted the construction of systematic sustainable development capabilities with ESG as the focus. It has achieved the comprehensive improvement of its ESG management system and the overall advancement of its management level on key ESG issues. Significant progress and results have been achieved in areas of cure, accessible, relationship, and environmental, providing strong support for the effective implementation of the Group's comprehensive innovation and internationalization strategies and laying a solid foundation for the Group's high-quality sustainable development. In 2025, Sino Biopharm will continue to deeply promote the integration of ESG with the Group's strategy and operations, and work with partners from all sectors to jointly build a high-quality industrial chain.

We firmly believe that the cause of human health and the path of sustainable development know no boundaries. In the future, Sino Biopharm will adhere to comprehensive innovation, actively embrace innovative technologies represented by AI, continuously launch good medicines that fill clinical gaps, and build globally competitive sustainable development capabilities. We will seek health and well-being for a wide range of patients and make substantial contributions to the harmonious progress of the company, society, and the environment.